ABSTRACT
INTRODUCTION
The characterization of gene function in vascular cells, including endothelial and smooth muscle cells (SMCs), has been limited by two major factors. First, suitable cell lines that maintain phenotypic and functional characteristics of primary vascular cells are lacking. Second, expression of exogenous genes has been difficult because of the extremely low transfection efficiency of primary vascular cells. As a result, many studies have been performed in cell lines of uncertain physiologic relevance and/or in primary vascular cells transduced at very low efficiencies.
An ideal strategy for gene expression in mammalian cells should meet several important criteria. First, stable and efficient transduction of primary, non-transformed cells should be possible to avoid the use of cell lines. The method of gene transduction should be nontoxic, and appropriate controls for expression of selectable markers should be used. Further, gene transduction and expression or selection should be rapid for use in primary cells with a limited in vitro replicative capacity. Additionally, transduced cells should be easily identified and, if necessary, isolated from polyclonal cell mixtures. Ideally, it should also be possible to vary gene expression levels to characterize gene dosage effects. Finally, analysis of gene function(s) should be possible within large polyclonal populations of transduced cells to avoid potential clonal artifacts.
Recent advances in expression techniques utilizing single-transcript retroviral vectors allow many of these criteria to be fulfilled for the first time using primary vascular cells. A limited number of recent studies have shown that single-transcript retroviral constructs can be used to efficiently transduce murine endothelial and canine vascular SMCs (12, 15) . However, systematic characterizations of the utility of these constructs in primary human vascular cells are not available. Here we demonstrate the utility of single-transcript retroviral vectors for the study of gene function in primary human endothelial cells and SMCs.
MATERIALS AND METHODS

Cell Culture and Reagents
Human umbilical vein endothelial cells (HUVECs) were isolated and cultured in RPMI 1640, supplemented with 15% FCS, 0.4% bovine pituitary brain extract (Invitrogen, Carlsbad, CA, USA), and 50 µg/mL heparin as previously described (4) . Human arterial SMCs were derived from the media of normal thoracic aortas by explant and were maintained in DMEM supplemented with 10% FCS. We used the following antibodies: anti-HA (clone HA.11; Babco, Richmond, CA, USA), anti-E-selectin (Clone 68-5H11; BD Pharmingen, San Diego, CA, USA), phycoerythrin (PE)-labeled anti-ICAM-1 (clone HA58; BD Pharmingen), and PE-labeled goat anti-mouse IgG (Biomeda, Foster City, CA, USA).
Protein Analysis
For immunoblotting, cells were lysed in 50 mM Tris-HCl, pH 7.4, 250 mM NaCl, 0.5% Nonidet ® P-40, 10% glycerol, 5 mM EDTA, 50 mM NaF, 0.5 mM Na 3 VO 4 , 10 mM β-glycerophosphate, PMSF, 5 µg/mL leupeptin and aprotinin. Lysates were separated on 10% or 15% SDS-PAGE, and proteins were transferred to Immobilon membranes (Millipore, Bedford, MA, USA) and immunoblotted with specific antibodies. Immunoblots were visualized by enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ, USA).
Generation of Retroviral Vectors, Retrovirus Production, and Infection of Endothelial Cells and SMCs
All retroviral expression plasmids were constructed using the pBMN-IRES-EGFP, pBMN-IRES-Lyt2a, and pBMN-IRES-PURO retroviral vectors and standard molecular biology techniques (8, 9) . The pBMN-IRES retroviral vectors contain a single-transcript expression cassette in which a retroviral promoter drives the expression of two genes. The pBMN-IRES-EGFP vector utilizes enhanced GFP (EGFP) as a second cistron reporter gene, pBMN-IRESLyt2a, a splice variant of murine CD8, and pBMN-IRES-PURO, the puromycin resistance gene. The cDNAs of human pro-HB-EGF, human MDC15, and human telomerase (hTERT) were cloned into the BamHI/NotI sites of pBMN-IRES-EGFP and IκBα-Ser into pBMN-IRES-Lyt2a. EGFP was cloned into the BamHI/NotI sites of pBMN-IRES-PURO.
Amphotrophic retrovirus was prepared with the use of Phoenix-A packaging cells as previously described (9) . After transfection of Phoenix-A packaging cells, the medium was changed at 10 h and again at 24 h after transfection. Virus collected between 24 and 48 h after transfection was used for infection. Retroviral titers between 10 6 and 2 × 10 7 cfu/mL were determined by limiting dilution with NIH3T3 cells. For infection, 4 × 10 5 HUVECs or SMCs were plated in 25-cm 2 flasks 24 h before infection in normal growth medium to obtain exponentially growing cultures. The medium was replaced with 4 mL retroviral supernatant (approximate MOI 2.5-25 cfu/cell) supplemented with 4 µg/mL polybrene.
After 12 h, retroviral supernatants were removed and replaced with fresh normal growth medium for 48 h. In these conditions, no apparent toxicity was observed after a 12-h exposure to retroviral supernatants containing polybrene in either HUVECs or SMCs.
Flow Cytometry
For the analysis of EGFP expression after retroviral infection, cells were harvested by brief trypsinization, washed in PBS, and fixed with 2% paraformaldehyde. The percentage of EGFP(+) cells was determined by flow cytometry by the use of a FACScan flow cytometer and analyzed with BD CellQuest (both from BD Biosciences, San Jose, CA, USA). For two-color analysis of cells expressing the CD8 (Lyt2) retroviral cell surface marker and an EGFP reporter gene, cells were stained with a PE-conjugated anti-CD8 antibody (BD Pharmingen) for 30 min on ice, followed by three washes in PBS + 0.25% BSA and post-fixed with 2% paraformaldehyde before analysis. Similarly, expression of adhesion molecules (E-selectin and ICAM-1) or hemagglutinin (HA)-tagged HB-EGF was determined by staining with biotinylated primary antibodies followed by PE-conjugated second antibodies. Cell-surface protein expression was quantified as the mean fluorescence intensity of greater than 10 000 gated cells.
RESULTS AND DISCUSSION
Single-transcript expression cassettes (STCs) are designed to allow the expression of two genes from a single mRNA. STCs contain a single promoter and two cistrons separated by an internal ribosomal entry site (IRES) sequence that allows eukaryotic ribosomes to initiate 5′-cap-independent translation of a second cistron gene (7, 13) ( Figure 1A ). Typical cassettes contain a gene of interest cloned into the first cistron and a selection or reporter gene, such as the EGFP, cloned into the second cistron. A major advantage of STCs is that expression of the second cistron reporter gene typically ensures expression of the first cistron gene. To determine the usefulness of retroviral vectors for introducing genes into HUVECs and human aortic SMCs, we infected these cells with pBM-IRES-EGFP retrovirus (8, 9) . In the absence of a first cistron gene, HUVECs and SMCs were infected at an infection efficiency of 93% and 75%, respectively, as determined by flow cytometric analysis of EGFP expression ( Figure 1B ). Similar results are seen using a specific antibody against a truncated cell-surface murine CD8 reporter gene in IRES-CD8-infected cells (not shown).
IRES-based retroviral vectors provide an effective strategy for delivering genes of varying sizes to primary vascular cells at high efficiency. We find that inclusion of a gene into the first cistron generally leads to decreased infection efficiencies with an inverse relationship between the size of the cDNA and the efficiency of retroviral infection ( Figure  1B ). However, infection efficiencies with a large 4.5-kb first cistron cDNA (hTERT) were still 56% and 45% for HUVECs and SMCs, respectively. Retroviral infection can also be used to simultaneously express two genes in primary vascular cells. Sequential infection of HUVECs with IRES-EGFP retrovirus followed by an IRES-CD8 retrovirus yields approximately 63% EGFP(+)CD8(+) cells by flow cytometry ( Figure 1C ). Alternatively, simultaneous co-infection with a 50:50 mixture of IRES-EGFP and IRES-CD8 retrovirus yields approximately 40% EGFP (+)CD8(+) cells ( Figure 1C ). Sequential and simultaneous infection of SMCs is also possible and yields approximately 20% and 11% EGFP(+)CD8(+) cells, respectively ( Figure 1C ). This approach is particularly useful in characterizing gene-gene interactions, such as the effect of overexpression of a wild-type versus a dominant negative mutant within a single polyclonal population of primary vascular cells.
Stable integration of IRES-based retroviral cassettes into the host cell genome allows for the isolation of purified populations of infected cells expressing different levels of reporter genes (therefore, cistron 1 genes) by flow cytometry. The metalloproteinasedisintegrin protein 15 (MDC15) is a 120-kDa cell-surface protein, encoded by a 2.5-kb cDNA, which is expressed by endothelial cells and SMCs in vitro MDC15 expression is stable over multiple passages in culture, cell sorting experiments were repeated using NIH3T3 cells that are a uniform replicative cell population capable of extended population doublings. Low and high expressing populations of NIH3T3 cells were subsequently subcultured for 3 or 11 passages (approximately 20 and 75 population doublings, respectively) ( Figure 2B ). The sorted NIH3T3 cells maintained their different expression levels as determined by flow cytometry and Western blot analysis ( Figure 2B ). These results demonstrate that EGFP reporter gene expression can be used to isolate distinct populations of cells expressing different levels of first cistron genes by flow cytometry and that stable levels of gene expression are maintained over multiple passages in vitro.
We next wanted to characterize further the correlation between expression of a reporter gene and a transmembrane protein cloned into the first cistron of an IRES-based retroviral vector in primary vascular cells. Pro-heparin-binding epidermal growth factor (Pro-HB-EGF) is a cell-surface growth factor that plays an important role in the migration and proliferation of vascular cells (14) . It has been shown previously that cell-surface levels of pro-HB-EGF can be monitored by analysis of a version of pro-HB-EGF containing an HA epitope tag at the N-terminus of the extracellular domain (3). HA-pro-HB-EGF was cloned into the IRES-EGFP retroviral vector and subsequently used for the infection of HUVECs, leading to the generation of distinct EGFP(-) and EGFP(+) populations by flow cytometry ( Figure 2C ). Coordinately, HA-HB-EGF expression was determined by the use of an antibody against the HA-epitope tag and a PE-conjugated secondary antibody. The correlation between EGFP and HA-HB-EGF expression was determined by gating on populations of cells expressing increasing levels of the EGFP reporter gene, followed by the measurement of the relative HB-EGF expression (PE mean fluorescence intensity) ( Figure 2C ). These results demonstrate an excellent correlation between the expression of the first cistron HA-HB-EGF and the second cistron EGFP reporter gene ( Figure 2C) . Moreover, the data show that expression levels achieved by retroviral transduction do not saturate the intracellular machinery responsible for the processing and cell-surface targeting of HB-EGF. Previous studies have shown that endothelial cells can be isolated by flow cytometry and subsequently used for functional analysis (10) after co-transfection with a plasmid expressing GFP and a second plasmid expressing a gene of interest. A major limitation of this approach is that expression of the GFP reporter and the gene of interest are not linked and are transient. In addition, although primary vascular cells can be sorted and subsequently subcultured (Figure 2A and data not shown), cell sorting is expensive, time consuming, and not readily available to many laboratories. Therefore, we generated an IRES-based retroviral vector expressing the puromycin resistance gene as a selectable second cistron gene (pBM-IRES-PURO) and tested the utility of this construct in generating highly purified populations of retrovirally infected primary human endothelial cells. Puromycin selection was chosen because puromycin very rapidly kills cells (1-2 days) and is inexpensive (6) . A test construct was also generated in which EGFP was cloned into the pBM-IRES-PURO vector as a first cistron gene and subsequently used to infect HUVECs at approximately 50% efficiency ( Figure  2D ). Infected cells were subsequently split into two populations and grown in the presence or absence of puromycin (2.5 µg/mL) for 24 h, and EGFP expression was determined by flow cytometry. Cells grown in the absence of puromycin remained approximately 50% EGFP(+), whereas those in the presence of puromycin were essentially 100% EGFP(+) after 24 h of selection ( Figure 2D ). An identical result is obtained with an overnight (12 h) puromycin selection (data not shown). Using this approach, we can obtain virtually 100% infected populations of primary endothelial cells within 24 h with ICAM-1) , which mediate the transmigration of circulating leukocytes into the extravascular space (2). The up-regulation of E-selectin and ICAM-1 is dependent on the activity of the transcription factor nuclear factor-κB (NF-κB), and inhibition of NF-κB activation blocks the up-regulation of Eselectin by inflammatory stimuli (1). Additionally, activity of the NF-κB transcription factor can be blocked by overexpression of the endogenous inhibitor of NF-κB (IκB-α), which contains mutations in two serine residues that prevent its degradation (17) . Therefore, we used this system to test the ability of IRES-CD8-based retroviral vectors to functionally define specific subpopulations of cells within polyclonal populations of infected endothelial cells. HUVECs were infected with either control IRES-CD8 or IκBα-Ser 32,36 -IRES-CD8 virus encoding an endogenous NF-κB inhibitor (17) . The resulting cell populations were stimulated with LPS for 3 or 6 h to monitor the expression of E-selectin and ICAM-1, respectively. In response to LPS, uninfected and CD8(-) or CD8(+) cells infected with the control IRES-CD8 virus showed a marked up-regulation of E-selectin and ICAM-1 ( Figure 3, A and B) . Expression strategies, such as those presented, should provide novel approaches for characterizing gene function in primary vascular cells. For example, we have recently shown that retroviral vectors can be used to efficiently deliver NF-κB-dependent reporter genes to primary HUVECs to characterize the ability of a co-transduced gene to activate the NF-κB pathway (11) . It should also now be possible to consider expression cloning strategies utilizing IRES-based retroviral cDNA libraries in primary vascular cells, as has recently been reported for other cell types (5). Finally, modifications of existing tetracycline-inducible retroviral expression systems should allow efficient and regulated gene expression in primary vascular cells with a limited in vitro replicative capacity (16) .
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